Oncolytic Viruses: An Approved Product on the Horizon?

Looking back over the past 15 years of oncolytic virus (OV) research, I cannot help being impressed by the creativity, ingenuity, and passion of those committed to seeing this platform succeed. Clever ideas that have led to novel targeting strategies, deciphering and exploitation of host–virus interactions, and innovative ways to deliver viruses to tumor beds are only a few of the basic science discoveries that have fueled excitement in the field.1,2,3 However, just as in professional sports where “winning is everything,” all that really matters in the end is what happens in the clinic.